- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01803087
Single-Dose Clinical Pharmacology Study in Asthmatic Adolescent and Adult Patients (ADO pMDI)
A SINGLE-DOSE, OPEN LABEL, RANDOMIZED, 3-WAY CROSSOVER, CLINICAL PHARMACOLOGY STUDY OF CHF 1535 100/6 pMDI (FIXED COMBINATION OF BECLOMETHASONE DIPROPIONATE 100 µg PLUS FORMOTEROL FUMARATE 6 µg) WITH OR WITHOUT SPACER DEVICE VERSUS THE FREE COMBINATION OF LICENSED BECLOMETHASONE pMDI AND FORMOTEROL pMDI IN ASTHMATIC ADOLESCENT PATIENTS AND ONE OPEN ARM FOR ADULT PATIENTS AS CONTROL GROUP TREATED WITH CHF 1535 100/6 pMDI.
Study Overview
Status
Conditions
Detailed Description
The proposed clinical pharmacology study is aimed to investigate the systemic availability of BDP/B17MP (active metabolite of BDP) and formoterol after single oral inhalation of CHF 1535 100/6 pMDI (to reach a total dose of BDP 400 µg and formoterol 24 µg) with and without spacer device (AeroChamber Plus™) and in comparison to a free combination of BDP pMDI plus formoterol pMDI licensed products (to reach the same total dose of BDP and formoterol) in adolescent asthmatic patients. The systemic exposure to BDP/B17MP and formoterol after inhalation of CHF 1535 pMDI in adolescents will be additionally compared to the systemic exposure in adults without the spacer device.
The chosen doses correspond to the maximum daily dose of the two components administered as fixed combination.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Lodz, Poland, 90153
- Uniwersytecki Szpital Kliniczny nr 1
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
- Inclusion criteria
Patients will be enrolled if they meet all of the following criteria:
- Male and female adolescents, aged ≥ 12 and < 18 years at the time of Screening Visit or male and female adults, aged ≥ 18 and ≤ 65 years at the time of Screening Visit.
- Written informed consent obtained by the patient in case of adult patients and by parents/legal representative and by the minor (according to local regulation).
- A diagnosis of asthma as defined in the GINA guidelines (updated 2010) 6 months before the screening visit.
- Male/female adolescent and adult patients with asthma stable enough, according to GINA guidelines (updated 2010) and based on the Investigator's opinion, to allow a wash out period from inhaled BDP of 2 days before each single day study treatments and any ICS other than BDP of 1 day before each single day study treatments.
- Male/female adolescents and adults asthmatic patients already treated with ICS or ICS/long-acting inhaled β2-agonists or using short-acting inhaled β2-agonists as reliever to control asthma symptoms.
- Adolescents and adults with a forced expiratory volume in one second (FEV1) > 70% of predicted values (% pred) after withholding short acting β2-agonist treatment for a minimum of 6 h prior to screening or 24 hours in case of long acting β2-agonist.
- Non- or ex-smokers who smoked less than 5 pack-years (e.g. < 20 cigarettes per day for 5 years) and stopped smoking for at least 1 year.
- A cooperative attitude and ability to be trained about the proper use of pMDI with and without a spacer device and compliant to study procedures.
Body mass index (BMI) ≥18.5 and ≤ 32 kg/m2
- Exclusion criteria
Patients will not be enrolled if one or more of the following criteria are present:
- Pregnant or breast-feeding female patients. Sexually active female not using efficient contraception throughout the entire study period (e.g. oestro-progestatives, condoms, intrauterine devices). A urinary pregnancy test will be performed at screening and treatment visits (mandatory in the adult population and at discretion of the investigator in the adolescent population) in women of childbearing potential;
- Having received an investigational drug within 2 months before the screening visit (Visit 1).
- Diagnosis of COPD, in the adult patients, as defined by the current GOLD guidelines (updated 2010).
- Known hypersensitivity to the active treatments.
- Inability to perform the required breathing technique and blood sampling.
- Hospitalization due to exacerbation of asthma within 1 month prior to the screening visit.
- Lower respiratory tract infection within 1 month prior to screening visit.
- Obesity, i.e. > 97% weight percentile by local standards.
- Significant medical history of and/or treatments for cardiac, renal, neurological, hepatic, endocrine diseases, that may interfere with patient's safety, compliance, or study evaluations, according to the Investigator's opinion;
- History of drug addiction or excessive use of alcohol (weekly intake in excess of 28 units alcohol; one unit being a glass of beer, wine or a measure of spirits), or excessive consumption of xanthine containing substances (daily intake in excess of 5 cups of coffee, tea, cola, etc) or psychological or other emotional problems likely to invalidate informed consent, or limit the ability of the subject to comply with the protocol requirements;
- Treatment with a xanthine derivative (e.g. theophylline) formulations in the 4 weeks prior to screening;
- Blood donation (450 mL or more) (for the adult population) or significant blood loss in the 12 weeks before the screening visit.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: CHF 1535 100/6 pMDI (Foster®) TEST 1
Adolescents CHF 1535 100/6, 4 puffs (total dose: BDP 400 µg/FF 24 µg) pMDI
|
|
Active Comparator: CHF 1535 100/6 pMDI (Foster®) AeroChamber Plus™ (TEST 2).
CHF 1535 100/6 pMDI (Foster®) using AeroChamber Plus™ spacer device in adolescents (TEST 2)
|
|
Active Comparator: (Qvar®: BDP 400 µg)+(Atimos®: formoterol 24 µg)
BDP 100 µg pMDI, 4 puffs (Qvar®, total dose: BDP 400 µg) + formoterol fumarate 6 µg pMDI, 4 puffs (Atimos®, total dose: formoterol 24 µg)
|
Other Names:
|
Active Comparator: CHF 1535 100/6, 4 puffs (total dose: BDP 400 µg/FF 24 µg) pMDI
Adults CHF 1535 100/6, 4 puffs (total dose: BDP 400 µg/FF 24 µg) pMDI
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
AUC0-t of B17MP CHF 1535 100/6 pMDI with and without spacer vs free combination of BDP pMDI and formoterol pMDI
Time Frame: : pre-dose (within 5 min from dosing), 5 min; 15 min; 30 min; 1, 2, 4, 6 and 8 hr after inhalation.
|
In adolescents, the systemic exposure of B17MP as AUC0-t, after inhalation of CHF 1535 100/6 pMDI with and without spacer device (AeroChamber Plus™) vs already licensed free combination of BDP pMDI and formoterol pMDI without spacer.
|
: pre-dose (within 5 min from dosing), 5 min; 15 min; 30 min; 1, 2, 4, 6 and 8 hr after inhalation.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
AUC0-t, AUC0-inf, Cmax, tmax and t½ for BDP and formoterol
Time Frame: : pre-dose (within 5 min from dosing), 5 min; 15 min; 30 min; 1, 2, 4, 6 and 8 hr after inhalation.
|
In adolescents, after inhalation of CHF1535 100/6 pMDI both with and without spacer vs a free combination of licensed BDP and Formoterol pMDIs.
|
: pre-dose (within 5 min from dosing), 5 min; 15 min; 30 min; 1, 2, 4, 6 and 8 hr after inhalation.
|
AUC0-0.5h, AUC0-inf, Cmax, tmax and t½ for B17MP
Time Frame: : pre-dose (within 5 min from dosing), 5 min; 15 min; 30 min; 1, 2, 4, 6 and 8 hr after inhalation.
|
In adolescents, after inhalation of CHF1535 100/6 pMDI both with and without spacer vs a free combination of licensed BDP and Formoterol pMDIs.
|
: pre-dose (within 5 min from dosing), 5 min; 15 min; 30 min; 1, 2, 4, 6 and 8 hr after inhalation.
|
plasma glucose and plasma potassium AUC0-t; Cmin; Tmin; Cmax; Tmax
Time Frame: : pre-dose (within 5 min from dosing), 5 min; 15 min; 30 min; 1, 2, 4, 6 and 8 hr after inhalation.
|
In adolescents, after inhalation of CHF 1535 100/6 pMDI with and without spacer (AeroChamber Plus™)vs fre combination
|
: pre-dose (within 5 min from dosing), 5 min; 15 min; 30 min; 1, 2, 4, 6 and 8 hr after inhalation.
|
Heart rate as AUC0-8h of CHF 1535 100/6 pMDI
Time Frame: pre-dose (within 5 min from dosing), 5 min; 10 min; 15 min; 30 min; 1, 2, 4, 6 and 8 hr after inhalation.
|
In adolescents, after inhalation of CHF1535 100/6 pMDI both with and without spacer vs free combination
|
pre-dose (within 5 min from dosing), 5 min; 10 min; 15 min; 30 min; 1, 2, 4, 6 and 8 hr after inhalation.
|
FEV1; time everaged FEV1 value AUC0-8h; peak FEV1
Time Frame: pre-dose; 30 min; 1, 2, 4, 6 and 8 hr after inhalation.
|
In adolescents, after inhalation of CHF1535 100/6 pMDI both with and without spacer vs a free combination of licensed BDP and Formoterol pMDIs.
|
pre-dose; 30 min; 1, 2, 4, 6 and 8 hr after inhalation.
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Immune System Diseases
- Lung Diseases
- Hypersensitivity, Immediate
- Bronchial Diseases
- Lung Diseases, Obstructive
- Respiratory Hypersensitivity
- Hypersensitivity
- Asthma
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Adrenergic Agonists
- Bronchodilator Agents
- Anti-Asthmatic Agents
- Respiratory System Agents
- Adrenergic beta-2 Receptor Agonists
- Adrenergic beta-Agonists
- Formoterol Fumarate
Other Study ID Numbers
- CCD-1104-PR-0062
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Asthma
-
Vanderbilt University Medical CenterNot yet recruitingAsthma in Children | Asthma Attack | Asthma Acute | Acute Asthma Exacerbation | Asthma; StatusUnited States
-
University of California, San FranciscoCompletedAsthma in Children | Asthma Attack | Asthma Acute | Asthma ChronicUnited States
-
SingHealth PolyclinicsNot yet recruitingAsthma | Asthma in Children | Asthma Attack | Asthma Acute | Asthma Chronic
-
Johann Wolfgang Goethe University HospitalCompleted
-
Universita di VeronaCompleted
-
Parc de Salut MarActive, not recruitingAsthma in Children | Persistent Asthma | Asthma ExacerbationSpain
-
Forest LaboratoriesCompleted
-
Brunel UniversityKarolinska InstitutetUnknown
-
Johann Wolfgang Goethe University HospitalCompletedExercise-induced AsthmaGermany
Clinical Trials on Test treatments CHF 1535 100/6 pMDI (Foster®) TEST1
-
Chiesi Farmaceutici S.p.A.Completed
-
Chiesi Farmaceutici S.p.A.Completed
-
Chiesi Farmaceutici S.p.A.CompletedChronic Obstructive Pulmonary DiseaseChina
-
Chiesi Farmaceutici S.p.A.CompletedChronic Obstructive Pulmonary DiseaseHungary
-
Chiesi Farmaceutici S.p.A.SGS S.A.Recruiting
-
Chiesi Farmaceutici S.p.A.CompletedChronic Obstructive Pulmonary DiseaseItaly, Germany, Hungary